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Background: The WW domain containing protein WWOX has been postulated to behave as a tumor suppressor in
breast and other cancers. Expression of this protein is lost in over 70% of ER negative tumors. This prompted us to
investigate the phenotypic and gene expression effects of loss of WWOX expression in breast cells.
Methods: Gene expression microarrays and standard in vitro assays were performed on stably silenced WWOX
(shRNA) normal breast cells. Bioinformatic analyses were used to identify gene networks and transcriptional
regulators affected by WWOX silencing. Co-immunoprecipitations and GST-pulldowns were used to demonstrate a
direct interaction between WWOX and SMAD3. Reporter assays, ChIP, confocal microscopy and in silico analyses
were employed to determine the effect of WWOX silencing on TGFβ-signaling.
Results: WWOX silencing affected cell proliferation, motility, attachment and deregulated expression of genes
involved in cell cycle, motility and DNA damage. Interestingly, we detected an enrichment of targets activated by
the SMAD3 transcription factor, including significant upregulation of ANGPTL4, FST, PTHLH and SERPINE1 transcripts.
Importantly, we demonstrate that the WWOX protein physically interacts with SMAD3 via WW domain 1.
Furthermore, WWOX expression dramatically decreases SMAD3 occupancy at the ANGPTL4 and SERPINE1 promoters
and significantly quenches activation of a TGFβ responsive reporter. Additionally, WWOX expression leads to
redistribution of SMAD3 from the nuclear to the cytoplasmic compartment. Since the TGFβ target ANGPTL4 plays a
key role in lung metastasis development, we performed a meta-analysis of ANGPTL4 expression relative to WWOX in
microarray datasets from breast carcinomas. We observed a significant inverse correlation between WWOX and
ANGPTL4. Furthermore, the WWOXlo/ANGPTL4hi cluster of breast tumors is enriched in triple-negative and basal-like
sub-types. Tumors with this gene expression signature could represent candidates for anti-TGFβ targeted therapies.
Conclusions: We show for the first time that WWOX modulates SMAD3 signaling in breast cells via direct
WW-domain mediated binding and potential cytoplasmic sequestration of SMAD3 protein. Since loss of WWOX
expression increases with breast cancer progression and it behaves as an inhibitor of SMAD3 transcriptional activity
these observations may help explain, at least in part, the paradoxical pro-tumorigenic effects of TGFβ signaling in
advanced breast cancer.
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WWOX (WW domain-containing oxidoreductase) was
originally cloned by our laboratory because it was ob-
served to reside in a chromosomal region (ch16q23)
commonly affected by deletions in breast cancer [1].
Subsequently, it was concluded that the second most
common chromosomal fragile site, FRA16D, spans the
same locus as WWOX [1,2]. It was determined that
FRA3B (FHIT) and FRA16D (WWOX) loci rank second
and third respectively, only after the CDKN2A (p16) locus,
as the chromosomal sites most commonly affected by
hemi- and homozygous deletions in a genome wide study
of over 740 cancer lines [3]. The high frequency of dele-
tions affecting WWOX in multiple solid tumors is well
documented [4-6]; additionally, translocations affecting
WWOX are common in multiple myeloma [7]. Loss of
WWOX expression is frequent in multiple tumor types in-
cluding breast cancer. Importantly, it has been determined
that over 70% of estrogen receptor alpha (ER) negative
breast cancers express little or no WWOX protein, sug-
gesting an inverse association between WWOX expression
and increasing breast cancer aggressiveness [8,9].
WWOX behaves as a suppressor of tumor growth in
some cancer lines [10-12]. Contradictory results were
reported withWwox KO mice that suffer from early life le-
thality; Aqeilan et al. reported osteosarcoma development
in someWwox KO newborn mice [13] whereas no neopla-
sias were detected in Wwox KO mice generated by our
laboratory [14]. Furthermore, we recently demonstrated
that no tumors develop spontaneously in mice targeted
for conditional deletion of Wwox in the mammary gland
[15]. Interestingly, Wwox ablation led to a significant in-
hibition of mammary gland ductal branching and impaired
alveologenesis. Based on these studies, we concluded that
WWOX does not behave as a classical tumor suppressor
gene in the normal mammary gland. Therefore, in order
to gain a better understanding of the role of WWOX in
breast epithelium we investigated the cellular and mo-
lecular effects of modulating WWOX expression levels
in normal, immortalized human breast cells.
Methods
Cell culture and reagents
All cell lines were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA) and validated
by DNA fingerprinting. MCF10 cells (ATCC #CRL-10318)
were cultured in DMEM/F12 supplemented with 5% fetal
bovine serum, 100 μg/mL hydrocortisone, 10 μg/mL
insulin, 20 ng/mL EGF, 1 ng/mL cholera toxin and 1%
penicillin-streptomycin. MCF7 cells (ATCC #HTB-22)
were cultured in modified IMEM supplemented with
10% fetal bovine serum. 184B5 cells (ATCC #CRL-8799)
were cultured in MEBM. Recombinant human TGFβ1
was purchased from R&D Systems.shRNA-mediated WWOX silencing in MCF10 cells
Cells were infected with the following shRNA-expressing
GIPZ lentiviruses (Open Biosystems) at an MOI of
5: scrambled control shRNA (RHS4348), shWWOX-A
(V2LHS_255213); shWWOX-B (V2LHS_255229) or
shWWOX (V2LHS_255213 and V2LHS_255229). Cells
were infected according to manufacturer’s instructions.
Stably WWOX silenced cells and controls were selected
with 2 μg/ml puromycin and WWOX protein level was
assayed by western blot.
Doxycycline-inducible WWOX expression system and
other transient transfections
pLVX-Tight-Puro from Clontech’s Tet-on advance system
(Clontech, Mountain View, CA) was used to construct
inducible WWOX expression. Full-length human WWOX
cDNA was amplified and inserted using BamH1/EcoR1
restriction enzyme sites. Lentiviral stocks were made
according to manufacturer’s protocol. MCF10 cells were
either stably or transiently infected by the lentiviruses
carrying the target cassettes and subjected to selection
with 2 μg/ml puromycin. One μg/ml of doxycycline were
used to induce WWOX expression.
Transient transfections were performed using FuGene 6
transfection reagent (Promega) and plasmids used were:
pCMV5b-FLAG-SMAD3 (Addgene plasmid 11742) [16],
3TP-LUX (Addgene plasmid 11767) [17], pRL Renilla
luciferase and pcDNA-Myc-WWOX.
Microarray data processing, bioinformatics and statistical
analyses
Total RNA was extracted from 3 biological replicates each
of MCF10 scrambled (Scr), MCF10 shWWOX-A and
MCF10 shWWOX-B using the RNeasy Mini kit (Qiagen).
Briefly, 2 μg of RNA from each of WWOX–silenced
sublines labeled with Cy5 were individually hybridized
on Agilent Whole Human Genome 4X44K microarrays
to analyze ~40000 transcripts (Agilent Technologies,
Palo Alto, CA, USA) using the RNA derived from the
corresponding MCF10 Scr sample (labeled with Cy3) as
reference. For RNA labeling, we used the Quick Amp
Kit (Agilent Technologies, Palo Alto, CA) by following
the manufacturer’s protocol. The hybridization steps
were carried out according to the Agilent protocol and
images were scanned using a Genepix 4000B microarray
scanner (Axon Instruments, Foster City, CA, USA).
Image analysis and initial quality control were per-
formed using Agilent Feature Extraction Software v10.2.
Raw datasets have been submitted to NCBI GEO data-
base with accession number GSE47371. We used the
limma Bioconductor package for background adjust-
ment (normexp method), within (Loess algorithm) and
between (quantiles method) arrays normalization [18].
To identify significantly up- or down-modulated genes
Ferguson et al. BMC Cancer 2013, 13:593 Page 3 of 11
http://www.biomedcentral.com/1471-2407/13/593within the hybridized samples (MCF10 shWWOX-A vs.
Scr and MCF10 shWWOX-B vs. Scr) we employed the
one-class Rank Products' test (q-value < 0.05; Fold
change > 2) [19]. Statistical analyses were done with the
MultiExperiment Viewer software (MeV 4.8) [20]. Dif-
ferentially expressed genes derived from both analyses
were compiled into one Excel spreadsheet pivot Table
for comparison of overlapping data between MCF10
shWWOX-A and MCF10 shWWOX-B WWOX sub-
lines. The number and identity of genes commonly
affected in both models was determined. We used the
normal approximation to the binomial distribution as
previously described [21] to calculate whether the number
of matching genes derived from each pairwise comparison
was of statistical significance (q < 0.05). Datasets were then
uploaded to IPA software for automated functional anno-
tation and gene enrichment analysis [22]. In addition, we
employed Enrichr online resource [23] for ChIP enrich-
ment analysis [24].
Clonal growth, attachment and cell motility assays
For clonal growth assays, 500 cells were plated into
individual wells of a 6-well plate. After 9 days of culture,
colonies were fixed and stained with crystal violet.
Digital images were used to determine the number and
area of growing colonies using ImageJ software 1.46
(NIH).
For attachment assays, cells (4×104 per well) were
seeded in serum-free medium on fibronectin, collagen
IV or laminin-coated 96-well plates (BD-BioCoat; BD)
and incubated for 120 min at 37°C/5% CO2. Adherent
cells were fixed at different time-points by adding a cold
10% TCA solution and then processed according to the
sulforhodamine B (SRB) assay (Sigma-Aldrich).
To assess cell motility we conducted a standard
wound-healing assay. Briefly, 1×106 cells were seeded in
each well. After cells adhered the FBS concentration in
the medium was reduced to 2% to decrease cell prolifera-
tion. Two scratch wounds were made in each well. Images
of the same fields were collected at 0 and 24 hrs. Wound
area expressed as percent of field of view was quantified
using the ImageJ software.
Real-time Q-PCR, ELISA, Western blotting and antibodies
RNA isolation and Real-time PCR was performed as
previously described [15]. Real-time assays were per-
formed using Sybr Green and the following primer sets:
FST F 5′-GCCACCTGAGAAAGGCTACC-3′, FST R
5′-TTACTGTCAGGGCACAGCTC-3′, ANGPTL4 F
5′- CACAGCCTGCAGACACAACT -3′, ANGPTL4 R
5′- AAACTGGCTTTGCAGATGCT -3′, PTHLH F 5′-
CGCTCTGCCTGGTTAGACTC-3′, PTHLH R 5′-AGA
ATCCTGCAATATGTCCTTGG-3′, SERPINE1 F 5′-GA
CCGCAACGTGGTTTTCTC-3′, SERPINE1 R 5′-CATCCTTGTTCCATGGCCCC-3′, 18S rRNA F 5′-ACGGAA
GGGCACCACCAGG-3′ and 18S rRNA R 5′-CACCAAC
TAAGAACGGCCATGC-3′. Experiments were done in
triplicate and normalized to 18S rRNA expression.
Levels of FST and ANGPTL4 proteins in conditioned
medium were determined using the FST Quantikine
ELISA kit and the ANGPTL4 DuoSet ELISA kit (R&D
Systems) according to manufacturer’s protocols. Briefly,
4×105 cells were seeded in phenol red-free DMEM/F12
medium supplemented with charcoal-stripped serum (5%)
and adequate growth factors under normal conditions for
72 hrs before collection of conditioned medium.
Western blotting was performed under standard condi-
tions by loading 20 μg of total protein per lane and trans-
ferring to PVDF membranes. Primary antibodies used
were: rabbit anti-WWOX (Aldaz lab), rabbit anti-SMAD3
(Cell Signaling), mouse anti-actin (Sigma-Aldrich) and
mouse anti-Myc (Origene). Secondary antibodies used
were: anti-rabbit HRP (Jackson Labs) anti-mouse HRP
(K&P Labs), anti-rabbit Alexa 594 and anti-mouse Alexa
488 (Invitrogen).
Co-immunoprecipitation, GST-pulldowns and Luciferase
assays
For co-immunoprecipitation, cells were lysed with a buffer
containing 50 nM Tris–HCl pH 7.4, 100 mM NaF, 10 mM
EDTA, 10 mM Na3VO4, 2 mM PMSF, 1% NP-40 and 0.5%
TritonX-100. Immunoprecipitations were carried out with
Protein A/G beads and washed five times in the same buf-
fer. Construction and purification of GST fusion proteins
was performed as previously described [25]. Pull-down
assays were performed using immobilized purified GST
or GST fusion proteins incubated with total cell lysate
from MCF10 cells transfected with 1 μg of pCMV5b-
Flag-SMAD3 plasmid for 48 hours.
For luciferase assays, MCF10 cells stably infected with
the described Dox-inducible WWOX expression system
were exposed to 1 μg/mL doxycycline for two days (or
no treatment). Cells were then co-transfected with 3TP-
LUX and pRL Renilla luciferase expressing control vector.
Serum-free media was applied and cells were then exposed
to 10 ng/mL TGFβ1 (or vehicle treatment) for 8 hours.
Luciferase assays were performed according to Dual-
Luciferase Assay protocol (Promega).
Chromatin immunoprecipitation (ChIP)
MCF10 cells transiently infected with the described
Dox-inducible WWOX expression system were exposed
to 1 μg/mL Dox for one day (or no treatment), changed
to serum-free media for 16 hours then exposed to
10 ng/mL TGFβ1 for 4 hours (or vehicle treatment).
ChIP was performed as described elsewhere [26].
Real-time PCR was performed to assay SMAD3 occupa-
tion at promoter elements via the percent input method.
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upstream from the ANGPTL4 transcriptional start site
were: F: 5′-GATTTGCTGTCCTGGCATCT-3′ and R:
5′-CTCCAAGCCAGCTCATTCTC-3′. Primers for the
SMAD binding element of the SERPINE1 promoter were:
F: 5′-GGGAGTCAGCCGTGTATCAT-3′ and R: 5′-TAG
GTTTTGTCTGTCTAGGACTTGG-3′ [27].
Confocal microscopy
Cells transiently transfected with pcDNA-Myc-WWOX
were seeded on round, glass coverslips in 12-well plates,
serum starved for 12 hours, treated with 20 ng/μL
TGFβ1 for 1 hour, fixed for 15 min in 4% PBS-buffered
paraformaldehyde, permeabilized with 0.05% Triton X-
100 in PBS (PBS-T) for 5 min, blocked with 1% bovine
serum albumin (BSA), and incubated with rabbit anti-
SMAD3 (Cell Signaling) overnight at 4°C then mouse
anti-Myc (Origene) for one hour at room temperature.
AlexaFluor-conjugated secondary antibodies were applied
for 2 hours at room temperature. Cells were washed three
times in PBS-T, DAPI solution applied, washed three more
times then mounted in Prolong Gold Anti-Fade (Invitro-
gen) on a microscope slide. Confocal microscopy was
done on a Zeiss LSM510 META confocal microscope with
100X plan-apochromatic objective and oil immersion. Im-
ages were acquired in sequential mode and single-color
controls were used to verify absence of crosstalk and
bleed-through.
WWOX and ANGPTL4 expression meta-analysis in breast
cancer datasets
To perform a comparative analysis of WWOX and
ANGPTL4 expression in breast cancer, we analyzed 819
primary carcinomas obtained from three independent
studies available in public databases. The fRMA pre-
processed expression matrixes of the studies GSE26639
(n = 226), GSE21653 (n = 266), and GSE20685 (n = 327)
were downloaded from the InSilico database [28].
These gene expression profiles were obtained using the
Affymetrix HG U133 Plus2 platform (GPL570). WWOX
and ANGPTL4 mRNA expression levels were estimated
by using the mean expression values of the Affymetrix
probes for each gene. We employed the Gaussian Mixture
Model to identify bimodal distributions in the expres-
sion levels of both genes [29]. Heatmap visualization of
WWOX and ANGPTL4 expression profiles was done
with the MultiExperiment Viewer software (MeV 4.8).
Results
WWOX silencing in breast cells affects clonal growth,
adhesion and motility
In order to gain insight into the consequences of loss of
WWOX expression we investigated the effects of WWOX
silencing in normal breast epithelial cells. To this end, weused an shRNA-mediated approach to stably knockdown
expression of WWOX in the normal human breast
cell line MCF10. Three independent stable WWOX
shRNA-expressing cell lines were generated (shWWOX,
shWWOX-A and shWWOX-B) and one scrambled shRNA
control. All three stably WWOX-silenced cell lines showed
a decrease of 80-90% WWOX protein expression levels
(Figure 1A).
We first investigated the effects of WWOX silencing
on the clonal growth of the MCF10 cells. We did not
detect differences in clonogenicity (i.e. number of
colonies) but found that MCF10 WWOX-silenced cells
proliferate more rapidly forming larger colonies than
their control scrambled shRNA counterparts (Figure 1B).
WWOX-silenced cells also displayed decreased attachment
to extracellular matrix components such as laminin,
collagen IV and fibronectin (Additional file 1) and were
significantly more motile, repopulating the wound faster
in the scratch wound-healing assay when compared with
controls (Figure 1C). In summary, our data suggests that
WWOX ablation influences cell proliferation, adhesion
and motility of breast cells.
Gene expression changes in normal human breast cells
silenced for WWOX expression
To determine global gene expression changes as a result
of WWOX silencing in normal human breast cells we
performed microarray studies. We compared two inde-
pendent shRNAs (shWWOX-A and shWWOX-B) target-
ing different regions of the WWOX transcript as a means
of ruling out any potential off-target effects. The statistical
analysis of the shWWOX-A and shWWOX-B gene expres-
sion profiles identified 328 commonly up-modulated and
344 commonly down-modulated genes (q value < 0.05) in
the two WWOX stably silenced cell lines (Figure 2A)
(Additional file 2). We used the Ingenuity Pathway
Analysis (IPA) resource for automated annotation and
classification of the common differentially expressed
genes. Among the statistically significant top biofunctions
deregulated in WWOX-silenced cells, we identified cell
cycle/proliferation, DNA replication, recombination and
repair as well as cellular movement (Figure 2B). These
biofunctions were consistent with the results from our
phenotypic assays as markers of proliferation such as
MKI67 and PCNA were both significantly upregulated
in WWOX silenced cells (Additional file 2). To identify
affected transcriptional regulatory networks, we per-
formed a ChIP enrichment analysis (ChEA) from the
commonly deregulated gene list. Briefly, ChEA identi-
fies over-representation of transcription factor targets
from a mammalian ChIP-X database [24]. ChEA allowed
us to identify a set of transcription factors that are the
most likely to have regulated WWOX associated gene ex-
pression changes. We detected a statistically significant
Figure 2 Effects of WWOX silencing on gene expression. (A) Venn diagram showing the overlap between transcripts up- or down-modulated
in two independent WWOX-silenced MCF10 sublines (fold-change >2.0, q < 0.05). (B) Top predicted biofunctions deregulated in WWOX-silenced
cells. Bar graph represents –log(p-value) for each biofunction. Biofunction prediction from IPA software. (C) ChIP enrichment analysis (ChEA) from
the commonly deregulated gene list. Bars represent the four transcription factors with the highest combined scores calculated by the Enrichr
resource, i.e. transcription factors more likely associated with the majority of gene expression changes observed (see also Additional file 2).
Figure 1 Silencing of WWOX results in increased clonal growth, decreased attachment and increased cell motility. (A) Western blot
demonstrating WWOX silencing in cell extracts from MCF10 control (Scr) and three independent stably WWOX-silenced cell lines. (B) Effect of
WWOX-silencing on clonal growth. Five hundred cells were seeded in each well of a 6-well plate for each subline and allowed to grow for 9 days.
Representative image of both conditions is shown. Bar graph represents the average of three independent experiments +/− SEM. (C) Scratch
wound healing assay. Results of four separate experiments done in biological triplicates (two wounds per well). Depicted is the average percent
of the difference between T0 and T24 from all experiments (±SEM).
Ferguson et al. BMC Cancer 2013, 13:593 Page 5 of 11
http://www.biomedcentral.com/1471-2407/13/593
Ferguson et al. BMC Cancer 2013, 13:593 Page 6 of 11
http://www.biomedcentral.com/1471-2407/13/593enrichment of E2F family members, SOX2 and SMAD3
gene targets (Figure 2C) (Additional file 2).Upregulation of SMAD3 target genes in WWOX silenced
cells
Interestingly, of the top 25 most upregulated genes in
WWOX-silenced cells 40% were SMAD3 target genes
(Additional file 2). Thus, SMAD3 appears as one of the
top transcriptional regulators likely responsible for many
of the gene expression changes detected by our micro-
array analysis. Among the group of most significantly
upregulated SMAD3 target genes we identified: FST
(5.2 fold), PTHLH (3.6 fold), ANGPTL4 (3.5 fold) and
SERPINE1 (2.5 fold). Real Time RT-PCR validations are
shown in Figure 3A. In order to explore whether this
finding was exclusive of MCF10 cells, we stably silenced
WWOX expression in another normal breast epithelial
cell line (184B5) and a breast cancer line (MCF7). Inter-
estingly, we observed a similar SMAD3 target gene
upregulation induced by WWOX silencing in those two
breast derived cell lines as well (Figure 3B-C).Figure 3 WWOX silencing results in increased expression of SMAD3 t
SMAD3-regulated genes in MCF10 (A) shWWOX subline (white bars) comp
three biological replicates of each stable cell line were used for quantitatio
Further real-time PCR validation of SMAD3 target upregulation in WWOX-si
184B5 normal breast cells (B) or MCF7 breast cancer cells (C). Significant up
with the exception of PTHLH expression in MCF7 cells. (D) ELISA assay for q
each MCF10 subline after 72 hours in culture (p < 0.01). (E) ELISA assay for
(F) Reversion of SMAD3 target gene upregulation by inducible ectopic WW
MCF10 shWWOX-A cells transiently transduced with a DOX-inducible WWO
(black bars) or without WWOX expression (white bars). 18S rRNA used as nSince the four aforementioned SMAD3 target genes
all produce secreted proteins, we tested by ELISA the
production of two of these proteins (ANGPTL4 and
FST) and detected significant increased secretion of
these proteins in cultured media from WWOX silenced
cells (Figure 3D-E).
To further investigate whether transcription of these
genes is regulated by WWOX expression status we
transiently transduced MCF10 WWOX-silenced cells
with a lentiviral, WWOX doxycycline-inducible system.
We determined that mRNA levels of each of the four
genes assayed decrease significantly when WWOX
protein is re-expressed (Figure 3F). Overall we demon-
strate that WWOX expression status influences the
expression of subsets of SMAD3-regulated genes.
WWOX inhibits TGFβ induced transcriptional activation
and decreases SMAD3 promoter occupancy
Since SMAD3 is a known TGFβ activated transcription
factor we investigated whether WWOX affects TGFβ-
dependent transcription using the 3TP-LUX luciferase re-
porter. This plasmid contains a strong TGFβ-responsivearget genes. (A-C) Validation of increased gene expression of
ared to Scr shRNA control (black bars) by Real Time qPCR. mRNA from
n, 18S rRNA was used as normalization control, (p < 0.01 for all genes).
lenced (shWWOX-B, white bars) or Scr shRNA control (black bars)
regulation was seen for all target genes in all WWOX-silenced samples
uantitation of ANGPTL4 protein concentration in culture media from
FST protein concentration in culture media from MCF10 sublines.
OX expression in MCF10 shWWOX-A cells. Real-Time PCR analysis of
X expression system. With induction of ectopic WWOX expression
ormalization control (p < 0.05 for all genes).
Figure 4 WWOX inhibits TGFβ-dependent transcription and
decreases SMAD3 occupancy at target gene promoters.
(A) 3TP-LUX luciferase reporter assay in MCF10 cells treated with or
without doxycycline to induce WWOX expression and with or
without TGFβ1 for 8 hours as indicated. Experiment done in
triplicate. (B-C) Chromatin immunoprecipitation of SMAD3 (or IgG
control) followed by qPCR in MCF10 cells transiently infected with
the doxycycline-inducible WWOX expression lentivirus system.
Primers used for qPCR span SMAD binding elements in the ANGPTL4
promoter (B) or the SERPINE1 promoter (C). Error bars represent SD
for all graphs.
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Activator inhibitor, PAI) promoter and is routinely used to
assay TGFβ signaling [17]. Indeed, we found that dox-
inducible expression of WWOX protein in MCF10 cells
significantly quenched TGFβ-dependent luciferase expres-
sion (Figure 4A).
We then asked whether WWOX expression in MCF10
cells would affect binding of SMAD3 to known DNA
responsive elements on the ANGPTL4 and SERPINE1 pro-
moters [27]. Using chromatin immunoprecipitation (ChIP)
we observed, as expected, a significant increase in SMAD3
presence at both promoters upon TGFβ1 treatment. How-
ever, when WWOX expression was induced we found a
dramatic loss of SMAD3 occupancy at both promoters
(Figure 4B-C). These results demonstrate that WWOX
protein expression affects SMAD3 protein availability for
binding effector promoter elements both in the idle state
and upon TGFβ1 stimulation.
WWOX interacts with SMAD3 via WW domain 1
The first WW domain of WWOX is a Class I WW do-
main known to bind to PPXY motifs on target proteins in
a phosphorylation-independent manner [25,30]. Since the
SMAD3 protein contains a 181PPGY184 motif we investi-
gated whether WWOX and SMAD3 proteins physically
interact. Indeed co-immunoprecipitation of endogenous
WWOX and SMAD3 proteins from MCF10 cell extracts
demonstrates a strong interaction between the two proteins
(Figure 5A). The SMAD3 coactivator RUNX2 is known to
bind both SMAD3 and WWOX [31,32] thus it was used as
a positive control for both co-immunoprecipitations. To
determine whether the observed interaction is dependent
upon WW1 domain of WWOX, GST-pulldown experi-
ments were performed. We observed that SMAD3 from
MCF10 whole cell lysates readily binds to the wild type
WW domains of WWOX but the interaction is lost
when the first WW domain is mutated (W44F/P47A)
(Figure 5B).
WWOX expression induces intracellular SMAD3
redistribution
WWOX is a cytoplasmic protein [10,25] while SMAD3
is predominantly found in the nuclear compartment. To
Figure 5 WWOX binds to SMAD3 and relocalizes it to the cytoplasm. (A) Co-immunoprecipitation of endogenous WWOX and SMAD3 from
MCF10 cells. Whole cell lysates were immunoprecipitated with either rabbit IgG (control), anti-WWOX, anti-SMAD3 or anti-RUNX2 antibodies. The
immunoprecipitates were immunoblotted with anti-WWOX and anti-SMAD3 antibodies as indicated. RUNX2 co-IP was used as a positive control
for both WWOX and SMAD3 interactions. (B) MCF10 cells were transfected with Flag-SMAD3 and pulldowns were performed with the indicated
GST fusion proteins either wild-type WW1 and 2 domains (GST-WT) or mutant WW1 (W44F/P47A) (GST-mut1) or GST alone. Bound protein was
detected by SMAD3 immunoblot. (C) Confocal microscopy of MCF10 cells transfected with pcDNA-Myc-WWOX and treated with TGFβ1. Note
how SMAD3 (green) localizes to the nucleus in cells with no Myc-WWOX expression (red) but undergoes intracellular redistribution mostly to the
cytoplasmic compartment in cells with ectopic WWOX expression (red). Images taken using a Zeiss LSM510 META confocal microscope and the
100X objective.
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subcellular localization, we used confocal microscopy to
analyze SMAD3 intracellular distribution with or with-
out WWOX ectopic expression. As expected, in MCF10
cells treated with TGFβ1, we found a predominantly
nuclear staining for SMAD3 (Figure 5C). Interestingly
however, induction of WWOX expression led to a cellu-
lar redistribution of SMAD3 protein levels shifting from
the nuclear to the cytoplasmic compartment and peri-
nuclear colocalization with WWOX.
WWOX and ANGPTL4 are inversely correlated in breast
cancer and the Wwoxlo/ANGPTL4hi cluster is enriched in
TNBC and basal-like cancers
Given the relevance of ANGPTL4 as a key determinant
of lung metastatic phenotypes for breast cancer cells
[33,34] and our observations of a clear inverse behavior
between WWOX and ANGPTL4 at the transcript and
protein level, we investigated whether this inverse rela-
tionship extended to breast cancers. To this end we per-
formed a meta-analysis using three independent gene
expression breast cancer datasets representing a total of
819 breast carcinoma samples. Unsupervised clustering
of these samples showed the emergence of two defined
clusters, cluster 1: WWOXhi/ANGPTL4lo and cluster 2:
WWOXlo/ANGPTL4hi representative of a statisticallysignificant negative correlation between WWOX and
ANGPTL4 expression (Figure 6). Further analysis of
breast tumor subtypes determined that the WWOXlo/
ANGPTL4hi cluster demonstrates a significant enrichment
of triple-negative breast cancer (TNBC) and basal-like
tumors (Cluster 2, p < 0.05). Overall, our analysis reveals
a significant inverse correlation between WWOX and
ANGPTL4 transcript levels in breast cancer patient
samples and that tumors with the WWOXlo/ANGPTL4hi
signature correlate with breast cancer subtypes charac-
terized by poor prognosis.
Discussion
It is clear that expression of WWOX is lost in breast
cancer and that this loss becomes more frequent as the
disease progresses [8,9,35,36]. Thus, we feel it is important
to understand the functions of WWOX in normal breast
cells and the effects of loss of expression of this protein in
breast cancer progression. In this study, we have described
the multiple consequences of WWOX silencing in nor-
mal human breast cells. WWOX knockdown leads to a
pro-transformation phenotype with increased prolifera-
tion, decreased attachment to ECM substrates and in-
creased cell motility. These phenotypes were supported
by corresponding changes in gene expression as genes
involved in cell cycle, DNA damage response and cell
Figure 6 WWOX AND ANGPTL4 expression meta-analysis in breast cancer datasets. Comparative analysis of WWOX and ANGPTL4 expression
in three independent gene expression studies of primary breast carcinomas. Unsupervised clustering resulted in two main groups, Cluster 1:
WWOXhi/ANGPTL4lo and Cluster 2 WWOXlo/ANGPTL4hi according to their gene expression profiles. We identified a statistically significant
enrichment of TNBC and basal-like breast carcinomas in cluster 2 from each dataset (p < 0.05).
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cells.
ChIP enrichment analysis identified SMAD3 as one
of the most over-represented transcription factors re-
sponsible for many of the observed gene expression
changes. Well known SMAD3 target genes such as FST,
ANGPTL4, PTHLH and SERPINE1 were found signifi-
cantly upregulated upon WWOX silencing. Interest-
ingly, ANGPTL4, PTHLH and SERPINE1 have all been
shown to be involved in breast cancer progression and
metastasis [33,37,38]. We observed that these specific
gene expression changes detected in WWOX knockdown
cells can be reverted upon WWOX re-expression. Fur-
thermore, we showed that WWOX protein expression sig-
nificantly decreases SMAD3 promoter occupancy at target
DNA elements and significantly decreases the response of
a TGFβ luciferase reporter.
These observations lead us to investigate whether
WWOX and SMAD3 physically interact with each other.
Indeed, we demonstrate for the first time that WWOX
is able to bind SMAD3 via the first WW domain and likely
modulates SMAD3 transcriptional activity by cytoplasmic
sequestration.
The effect of TGFβ signaling in breast cells has been
described as paradoxical since it acts as an inhibitor of
growth in normal mammary epithelium [39] but transitionsto being an enhancer of tumor progression in advanced
breast cancer stages [40-42]. The mechanisms behind this
dichotomous behavior are poorly understood [43]. In nor-
mal mammary epithelial cells TGFβ inhibits cell growth
by inducing the expression of cell cycle inhibitors such as
CDKN2B (p15) and CDKN1A (p21) and repressing the
expression of cell cycle activators such as MYC [44-46].
On the other hand, in advanced-stage breast cancer the
growth inhibitory effects of genes such a p15 and p21 are
no longer effective and different subsets of pro-oncogenic
and pro-metastatic genes are activated by TGFβ [40-42].
In fact the majority of breast cancers demonstrate active
signaling through the TGFβ pathway and some tumors
secret high levels of TGFβ [40].
SMAD protein family members are known to be regu-
lated by a number of WW-domain containing proteins
such as YAP, PIN1, NEDD4L and SMURF1/2 [47,48]. YAP
and PIN1 interact with SMADs in a phosphorylation-
dependent manner and stabilize SMAD-cofactor binding
at promoter elements to enhance transcriptional effects
[47]. NEDD4L and SMURF1/2 are E3 ubiquitin ligase
proteins responsible for SMAD protein turnover [43,47].
WWOX, also a WW domain containing cytoplasmic pro-
tein, is known to physically interact with the PPXY motif
of various transcription factors via such domains and it
has been postulated that one of its mechanisms of action
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transcriptional activity [5,49]. In this study, we propose
that via the same mechanism WWOX acts as an inhibitor
of TGFβ signaling by binding to SMAD3 and modulating
nuclear translocation of this transcription factor, thus
reducing promoter occupation and transcriptional acti-
vation. In the absence of WWOX, a condition that
emulates advanced breast cancer, SMAD3 can enter the
nucleus uninhibited. Promoter specificity and activation
of pro-metastatic genes such as ANGPTL4, PTHLH and
SERPINE1, depends on SMAD3 interaction with specific
transcriptional co-activators such as RUNX2. RUNX2 is a
SMAD3 coactivator that has been shown to induce EMT
[50] and pro-metastatic genes such as ANGPTL4 [33] in a
TGFβ-dependent manner. Interestingly, it has been previ-
ously demonstrated that WWOX also binds to RUNX2
(Figure 5A) and modulates its transcriptional activity [32].
The ability of WWOX to affect the transcriptional activity
of not only SMAD3 but also of a key transcriptional cofac-
tor such as RUNX2 suggests that the presence or absence
of WWOX could be critical for modulating TGFβ signal-
ing and, more importantly, for the activation or repression
of specific transcriptional targets known to be associated
with tumor progression. Interestingly, our breast cancer
gene expression meta-analysis indicates an inverse correl-
ation between WWOX and ANGPTL4. Furthermore, tu-
mors with the WWOXlo/ANGPTL4hi signature correlate
with breast cancer subtypes characterized by poor progno-
sis. Thus, the WWOXlo/ANGPTL4hi breast cancer subset
could represent good candidates for exploring anti-TGFβ
therapeutic approaches.Conclusions
Loss of WWOX expression leads to significant upmodula-
tion of SMAD3 transcriptional activity leading to overex-
pression of multiple gene targets associated with breast
cancer progression. WWOX directly binds SMAD3 via
WW domain 1 and inhibits its transcriptional activity by
sequestering this transcription factor in the cytoplasmic
compartment.
In summary, we hypothesize that the progressive loss of
WWOX expression in advanced breast cancer contributes
to deregulating the TGFβ pathway and, more importantly,
may explain some of the pro-metastatic effects resulting
from TGFβ/SMAD3 hyperactive signaling in advanced
breast cancer.Additional files
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